Pacific Biosciences Q2 2024 Adj. EPS $(0.20) Beats $(0.23) Estimate, Sales $36.013M Miss $40.878M Estimate
Author: Benzinga Newsdesk | August 07, 2024 04:53pm
Pacific Biosciences (NASDAQ:
PACB) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.23) by 13.04 percent. The company reported quarterly sales of $36.013 million which missed the analyst consensus estimate of $40.878 million by 11.90 percent. This is a 24.30 percent decrease over sales of $47.573 million the same period last year.
Posted In: PACB